In terms of pancreatic cancer, Liu and colleagues demonstrated that the overexpression of circHIPK3 remarkably downregulated miR-330-5p-activated RAS-association domain family 1 (RASSF1) expression, stimulating the carcinogenesis and progression and becoming immune to gemcitabine therapy of pancreatic cancer cells [80]. This evidence concerns the gene RASSF1 and familial pancreatic carcinoma.